本文選題：藥品價格 + 價格形成機制　； 參考：《中國藥房》2017年24期

【摘要】：目的:為我國制定合理的藥品醫(yī)保支付價格提供借鑒。方法:通過檢索分析國內(nèi)外正式發(fā)表的學(xué)術(shù)文章、官方網(wǎng)站和政府文件、新聞報道等資料和知情人訪談,總結(jié)國際主要藥品醫(yī)保支付價格形成機制,高值藥可持續(xù)的公平可及的解決方式,為我國制定合理的藥品價格政策提出建議。結(jié)果與結(jié)論:國際通用的醫(yī)藥支付價格的確定依據(jù)為內(nèi)部參考定價法、增量成本-效果評價法、外部參考定價法。國際社會還采取以公平藥價計劃、藥品專利池、開源藥物研發(fā)組織等形式促進高值藥可持續(xù)地公平可及。我國實現(xiàn)全民醫(yī)保目標(biāo)后,應(yīng)積極探索制定合理的醫(yī)保支付價格。可以在仿制藥質(zhì)量和臨床療效一致性評價后,采用內(nèi)部參考定價法確定有仿制藥競爭品種的支付標(biāo)準(zhǔn),采用外部參考定價法或增量成本-效果評價法確定創(chuàng)新專利藥品價格談判的參考價格,對高值藥物采用公平定價的理念。
[Abstract]:Objective: to provide reference for the establishment of reasonable medical insurance payment price in China. Methods: through the retrieval and analysis of published academic articles, official websites and government documents, news reports and interviews with insiders, the formation mechanism of international major drug insurance payment price was summarized. Sustainable, fair and accessible solutions for high-value drugs are proposed for the formulation of reasonable drug price policies in China. Results & conclusion: the international general pricing of pharmaceutical payment is based on internal reference pricing, incremental cost-effect evaluation and external reference pricing. The international community also promotes sustainable and equitable access to high-value drugs in the form of fair drug pricing schemes, drug patent pools, and open source drug research and development organizations. After our country realizes the goal of universal medical insurance, we should actively explore the reasonable medical insurance payment price. After evaluating the consistency between the quality and clinical efficacy of generic drugs, the internal reference pricing method can be used to determine the payment criteria for competing varieties of generic drugs. The external reference pricing method or incremental cost-effect evaluation method is used to determine the reference price of the innovative patent drug price negotiation, and the fair pricing concept for high value drugs is adopted.
【作者單位】： 中國醫(yī)學(xué)科學(xué)院北京協(xié)和醫(yī)學(xué)院公共衛(wèi)生學(xué)院;
【基金】：中央級公益性科研院所基本科研業(yè)務(wù)費項目 國家衛(wèi)生計生委藥政司委托研究課題(No.藥政[2016]9號)
【分類號】：R951
，

本文編號：2029123